Table 1.

Association of high NOS2 expression with tumor characteristics

Clinicopathological characteristiciNOS (n = 90)NICD (n = 90)
OR (95%CI)POR (95%CI)P
Gender (male/female)3.5 (0.86–14.22)0.0792.96 (0.74–11.83)0.125
Age, y (<60/≥60)1.63 (0.62–4.31)0.3241.40 (0.53–3.69)0.494
Grade (1/2/3 stage)1.61 (0.59–4.38)0.3501.89 (0.69–5.17)0.213
Microsatellites (absence/presence)2.38 (0.52–10.9)0.2614.66 (1.0821.93)0.05*
Tumor size (<5 cm/≥5 cm)1.38 (0.48–3.96)0.5500.54 (0.19–1.56)0.256
Gross classification (massive/nodular/diffuse type)0.78 (0.23–2.67)0.6860.66 (0.19–2.28)0.513
Venous infiltration (absence/presence)4.80 (1.2218.65)0.025*14.24 (3.1165.15)0.0006**
TNM stage (low/high)3.72 (1.1112.52)0.034*3.37 (1.0111.23)0.048*
CD24 (low/high)2.80 (1.704.62)0.032*2.53 (1.016.37)0.049*
CD133 (low/high)1.36 (1.573.23)0.049*2.55 (1.653.72)0.033*
  • The IHC score of iNOS, TACE/Adam17, and activated Notch (NICD) in HCC was stratified into low, moderate, strong, and high for the analysis. “Low” is defined as expression less than onefold relative to mean values in normal tissue, whereas “high” is defined as expression greater than twofold relative to mean values in normal tissue. “Intermediate” expression is the range between low and high. Logistic regression was performed, with adjustments for age at diagnosis, gender, TNM stage, and neoadjuvant therapy. TNM stage was stratified into low (stage I/II) and high (stage III/IV). CD24 and CD133 counts were stratified into low (below the median) versus high (above the median).

  • * P < 0.05, **P < 0.01; significant difference (logistic regression, χ2 test). Numbers in boldface font indicate statistical difference.